

CITATION REPORT

List of articles citing

New therapeutic strategies in systemic lupus erythematosus management

DOI: 10.1038/s41584-018-0133-2

Nature Reviews Rheumatology, 2019, 15, 30-48.

Source: <https://exaly.com/paper-pdf/74753343/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
88	Potential role of melatonin in autoimmune diseases. <i>Cytokine and Growth Factor Reviews</i> , 2019 , 48, 1-10	17.9	23
87	Preclinical and early systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019 , 33, 101422	5.3	9
86	Individualizing Therapy in Lupus Nephritis. <i>Kidney International Reports</i> , 2019 , 4, 1366-1372	4.1	4
85	Novel paradigms in systemic lupus erythematosus. <i>Lancet, The</i> , 2019 , 393, 2344-2358	40	186
84	Risks and benefits of corticosteroids in arthritic diseases in the clinic. <i>Biochemical Pharmacology</i> , 2019 , 165, 112-125	6	12
83	Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission. <i>Rheumatology</i> , 2020 , 59, 1591-1598	3.9	18
82	Lupus Erythematosus. 2020 , 472-476		
81	Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort. <i>Rheumatology</i> , 2020 , 59, 2272-2281	3.9	11
80	Molecular mechanism of celastrol in the treatment of systemic lupus erythematosus based on network pharmacology and molecular docking technology. <i>Life Sciences</i> , 2020 , 240, 117063	6.8	13
79	Drug delivery to macrophages: A review of targeting drugs and drug carriers to macrophages for inflammatory diseases. <i>Advanced Drug Delivery Reviews</i> , 2020 , 165-166, 15-40	18.5	75
78	Interleukin-17 and lupus: enough to be a target? For which patients?. <i>Lupus</i> , 2020 , 29, 6-14	2.6	16
77	Prevalence, predictors and prognostic benefits of remission achievement in patients with systemic lupus erythematosus: a systematic review. <i>Arthritis Care and Research</i> , 2020 ,	4.7	0
76	[Therapeutic de-escalation in systemic lupus erythematosus in remission]. <i>Revue De Medecine Interne</i> , 2020 , 41, 795-799	0.1	0
75	Lupus nephritis: clinical presentations and outcomes in the 21st century. <i>Rheumatology</i> , 2020 , 59, v39-v51	31.9	24
74	Mapping systemic lupus erythematosus heterogeneity at the single-cell level. <i>Nature Immunology</i> , 2020 , 21, 1094-1106	19.1	63
73	LncRNA inhibition of TDP43 cleavage suppresses IRF3-initiated antiviral innate immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 23695-23706	11.5	41
72	Clinical practice guidelines and recommendations for the management of patients with systemic lupus erythematosus: a critical comparison. <i>Rheumatology</i> , 2020 , 59, 3690-3699	3.9	5

71	Influence of total western diet on docosahexaenoic acid suppression of silica-triggered lupus flaring in NZBWF1 mice. <i>PLoS ONE</i> , 2020 , 15, e0233183	3.7	4
70	MicroRNA-125a-Loaded Polymeric Nanoparticles Alleviate Systemic Lupus Erythematosus by Restoring Effector/Regulatory T Cells Balance. <i>ACS Nano</i> , 2020 , 14, 4414-4429	16.7	25
69	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1314-1324	9.5	24
68	Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2020 , 59, 3400-3407	3.9	4
67	Lupus Low Disease Activity State Achievement Is Important for Reducing Adverse Outcomes in Pregnant Patients With Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2021 , 48, 707-716	4.1	7
66	The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis. <i>Rheumatology</i> , 2021 , 60, 60-72	3.9	13
65	Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion. <i>Rheumatology</i> , 2021 , 60, 1313-1320	3.9	5
64	Association of Urinary Matrix Metalloproteinase 7 Levels With Incident Renal Flare in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 265-275	9.5	3
63	Orofacial manifestations and dental management of systemic lupus erythematosus: A review. <i>Oral Diseases</i> , 2021 , 27, 151-167	3.5	14
62	Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	1
61	Lupus erythematosus: Significance of dermatologic findings. <i>Annales De Dermatologie Et De Venereologie</i> , 2021 , 148, 6-15	0.3	0
60	Regulatory Effect of Mesenchymal Stem Cells on T Cell Phenotypes in Autoimmune Diseases. <i>Stem Cells International</i> , 2021 , 2021, 5583994	5	3
59	Belimumab: a step forward in the treatment of systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 563-573	5.4	4
58	Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. <i>Rheumatology</i> , 2021 ,	3.9	1
57	SLE-DAS in the First Trimester of Gestation Predicts Maternal Lupus Flares Later in Pregnancy. <i>Frontiers in Pharmacology</i> , 2021 , 12, 660123	5.6	2
56	A STING antagonist modulating the interaction with STIM1 blocks ER-to-Golgi trafficking and inhibits lupus pathology. <i>EBioMedicine</i> , 2021 , 66, 103314	8.8	3
55	Psychoeducational Intervention Benefits the Quality of Life of Patients with Active Systemic Lupus Erythematosus. <i>Journal of Nanomaterials</i> , 2021 , 2021, 1-8	3.2	
54	Increased Proportion of CD226 B Cells Is Associated With the Disease Activity and Prognosis of Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2021 , 12, 713225	8.4	1

53	The immunosuppressive activity of artemisinin-type drugs towards inflammatory and autoimmune diseases. <i>Medicinal Research Reviews</i> , 2021 , 41, 3023-3061	14.4	15
52	Predicting lupus low disease activity state and remission in SLE: novel insights. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 1083-1089	5.1	0
51	Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1568-1574	2.4	1
50	Uso de la balneoterapia y el ejercicio terapéutico en la mejora física y psicosocial en adolescentes con lupus y artritis juvenil: un estudio de método mixto. <i>Fisioterapia</i> , 2021 ,	0.2	
49	Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021 , 59, 367-383	0.9	3
48	Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	2
47	Is There a Place for Chimeric Antigen Receptor-T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases?. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1954-1965	9.5	7
46	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. <i>Journal of Autoimmunity</i> , 2021 , 124, 102729	15.5	3
45	Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren's syndrome: a literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X211040696 ²	2.8	2
44	Identification of key biomarkers and immune infiltration in systemic lupus erythematosus by integrated bioinformatics analysis. <i>Journal of Translational Medicine</i> , 2021 , 19, 35	8.5	18
43	Systemic lupus erythematosus: new horizons for diagnosis and therapy. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020 , 58, 5-14	0.9	12
42	Central Nervous System Vasculitis and Related Diseases. <i>Contemporary Clinical Neuroscience</i> , 2019 , 651-682		
41	New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021 , 59, 537-546	0.9	2
40	Factors associated with self-reported capacity to walk, jog and run in individuals with systemic lupus erythematosus. <i>Archives of Rheumatology</i> , 2021 , 36, 89-100	0.9	
39	Controversies in Systemic Lupus Erythematosus: Are We Treating Our Patients Adequately?. <i>Journal of Clinical Rheumatology</i> , 2021 ,	1.1	1
38	Toll-like Receptor Signaling Inhibitory Peptide Improves Inflammation in Animal Model and Human Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	0
37	Lupus Academy: Keeping Education Live, Virtually.. <i>Journal of European CME</i> , 2021 , 10, 2014041	0.6	0
36	Discovery and mechanistic study of thiazole-4-acylsulfonamide derivatives as potent and orally active ChemR23 inhibitors with a long-acting effect in cynomolgus monkeys.. <i>Bioorganic and Medicinal Chemistry</i> , 2022 , 56, 116587	3.4	0

35	Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in lupus women: the French GR2 study.. <i>Rheumatology</i> , 2022 ,	3.9	2
34	Cell-type-specific transcriptome architecture underlying the establishment and exacerbation of systemic lupus erythematosus.		
33	Treat-to-target in systemic lupus erythematosus: advancing towards its implementation.. <i>Nature Reviews Rheumatology</i> , 2022 ,	8.1	2
32	Evaluation of combination therapy with etanercept and systemic corticosteroids for Stevens-Johnson syndrome and toxic epidermal necrolysis: A multicenter observational study.. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022 ,	5.4	0
31	Macrophage-Associated Disorders: Pathophysiology, Treatment Challenges, and Possible Solutions. 2022 , 65-99		0
30	A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus.. <i>Rheumatology and Therapy</i> , 2022 , 1	4.4	0
29	Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Analysis of Three Phase III Clinical Trials of Belimumab.. <i>Frontiers in Immunology</i> , 2022 , 13, 796508	8.4	1
28	Definition of Low Disease Activity State based on the SLE-DAS: Derivation and validation in a multicentre real-life cohort. <i>Rheumatology</i> , 2021 ,	3.9	0
27	Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal.. <i>Rheumatology</i> , 2022 ,	3.9	2
26	LangChuangHeJi decoction ameliorates lupus via preventing accumulation of CD138+ T cells in MRL/lpr mice.. <i>American Journal of Translational Research (discontinued)</i> , 2021 , 13, 12440-12460	3	
25	Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis.. <i>Lupus Science and Medicine</i> , 2022 , 9,	4.6	0
24	Clinical Values of the Identified Hub Genes in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 13,	8.4	
23	Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment. <i>Expert Opinion on Biological Therapy</i> , 2022 , 22, 821-829	5.4	1
22	Cross Talk between Mesenchymal Stem/Stromal Cells and Innate Immunocytes Concerning Lupus Disease. <i>Stem Cell Reviews and Reports</i> ,	7.3	0
21	Defining the targets in SLE management: insights and unmet gaps. ard-2022-222991		0
20	Korean LupusPRO: Cross-Cultural validation study for systemic lupus erythematosus. 096120332211229		
19	Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus. 2022 , 21, 103165		
18	Systemic lupus erythematosus: history and modernity. 2022 , 60, 397-412		2

- 17 Rapamycin-encapsulated costimulatory ICOS/CD40L-bispecific nanoparticles restrict pathogenic helper T-B-cell interactions while in situ suppressing mTOR for lupus treatment. **2022**, 289, 121766 ○
- 16 Exploratory Analysis of Outpatient Visits for US Adults Diagnosed with Lupus Erythematosus: Findings from the National Ambulatory Medical Care Survey 2006-2016. **2022**, 10, 1664 ○
- 15 B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools. 9, 1
- 14 Increased sIL-2R α leads to obstruction of IL-2 biological function and Treg cells differentiation in SLE patients via binding to IL-2. 13, ○
- 13 Chinese SLE Treatment and Research Group Registry (CSTAR) XIV: the subjective well-being of patients with systemic lupus erythematosus. 9, ○
- 12 Chlorogenic Acid Relieves the Lupus Erythematosus-like Skin Lesions and Arthritis in MRL/lpr Mice. **2022**, 15, 1327 ○
- 11 Reduced Rate of Disease Flares in Japanese Patients with Systemic Lupus Erythematosus: An Altered Balance between the Use of Glucocorticoids and Immunosuppressants in Recent Decades. **2022**, 61, 3189-3196 1
- 10 Degradation of HDAC10 by autophagy promotes IRF3-mediated antiviral innate immune responses. **2022**, 15, ○
- 9 Unraveling the Link between Interferon- β and Systemic Lupus Erythematosus: From the Molecular Mechanisms to Target Therapies. **2022**, 23, 15998 ○
- 8 Systemic lupus erythematosus incidence and prevalence in a large population-based study in northeastern Italy. ○
- 7 Envisager la d'escalade thérapeutique au cours du Lupus Erythémateux Systémique : du concept de T2 T β à celui de T2U. **2022**, ○
- 6 Differential renal expression of IFN- β and BAFF and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis. ○
- 5 Mortality and causes of death in systemic lupus erythematosus over the last decade: Data from a large population-based study. **2023**, ○
- 4 Lipidome modulation by dietary omega-3 polyunsaturated fatty acid supplementation or selective soluble epoxide hydrolase inhibition suppresses rough LPS-accelerated glomerulonephritis in lupus-prone mice. 14, ○
- 3 Immunopathogenesis of systemic lupus erythematosus. **2023**, 265-292 ○
- 2 Functional Genome Analysis for Immune Cells Provides Clues for Stratification of Systemic Lupus Erythematosus. **2023**, 13, 591 ○
- 1 Delivery of AntagomiR-7 through polymer nanoparticles for assisting B Cell to alleviate systemic lupus erythematosus. 11, ○